Javascript must be enabled to continue!
DIDA-Seq Custom Capture cfDNA Library Preparation v1
View through CrossRef
Dual Index Degenerate Adaptor Sequencing, or DIDA-Seq, an ultra-sensitive cell-free DNA sequencing approach for the detection and quantification of circulating tumor DNA in peripheral blood plasma at fractions below the background error-rate of traditional next-generation sequencing (NGS). DIDA-Seq combines unique molecular identifiers (UMIs) and patient-specific custom capture panels to routinely detect ctDNA with mutation allele frequencies at or below 0.02% (or 1 tumor derived DNA fragment in 5k normal fragments at a given genomic locus) with error-rates below 1 base in 10kb-50kb (Butler et al 2019, doi:10.1101/mcs.a003772; Boniface et al 2021, doi:10.3390/diagnostics11010073). This protocol describes the preparation of DIDA-Seq libraries using cell-free DNA, custom DIDA-seq library adaptors and blocking oligonucleotides, and custom hybridization capture panels. It uses reagents developed and manufactured by Roche, LTD and Integrated DNA Technologies, Inc with minimally modified versions of their methods.
Title: DIDA-Seq Custom Capture cfDNA Library Preparation v1
Description:
Dual Index Degenerate Adaptor Sequencing, or DIDA-Seq, an ultra-sensitive cell-free DNA sequencing approach for the detection and quantification of circulating tumor DNA in peripheral blood plasma at fractions below the background error-rate of traditional next-generation sequencing (NGS).
DIDA-Seq combines unique molecular identifiers (UMIs) and patient-specific custom capture panels to routinely detect ctDNA with mutation allele frequencies at or below 0.
02% (or 1 tumor derived DNA fragment in 5k normal fragments at a given genomic locus) with error-rates below 1 base in 10kb-50kb (Butler et al 2019, doi:10.
1101/mcs.
a003772; Boniface et al 2021, doi:10.
3390/diagnostics11010073).
This protocol describes the preparation of DIDA-Seq libraries using cell-free DNA, custom DIDA-seq library adaptors and blocking oligonucleotides, and custom hybridization capture panels.
It uses reagents developed and manufactured by Roche, LTD and Integrated DNA Technologies, Inc with minimally modified versions of their methods.
Related Results
Abstract 468: BRAF mutation analysis in cell free tumoral DNA (cfDNA) of melanoma patients: results from the prospective study GEM1304 (Spanish Melanoma Group)
Abstract 468: BRAF mutation analysis in cell free tumoral DNA (cfDNA) of melanoma patients: results from the prospective study GEM1304 (Spanish Melanoma Group)
Abstract
Backgroud: Tumor-derived circulating cell-free DNA (cfDNA) is a dynamic source for determination of tumor mutation status. We have previously demonstrated t...
Abstract 1694: Cytotoxic conditions alter cell free DNA concentration and fragment size in cancer cells
Abstract 1694: Cytotoxic conditions alter cell free DNA concentration and fragment size in cancer cells
Abstract
Introduction: Detection of circulating free DNA (cfDNA) is a promising tool to monitor and predict tumor progression and treatment efficacy. Our group has s...
Monitoring of Cell-free Human Papillomavirus DNA in Metastatic or Recurrent Cervical Cancer: Clinical Significance and Treatment Implications
Monitoring of Cell-free Human Papillomavirus DNA in Metastatic or Recurrent Cervical Cancer: Clinical Significance and Treatment Implications
PURPOSE: Monitoring of circulating human papillomavirus (HPV) cell-free DNA (cfDNA) is a minimally invasive approach for surveillance in HPV-associated cancers, particularly cervic...
Monitoring of Cell-free Human Papillomavirus DNA in Metastatic or Recurrent Cervical Cancer: Clinical Significance and Treatment Implications
Monitoring of Cell-free Human Papillomavirus DNA in Metastatic or Recurrent Cervical Cancer: Clinical Significance and Treatment Implications
Abstract
Purpose
Monitoring of circulating human papillomavirus (HPV) cell-free DNA (cfDNA) is a minimally invasive approach for surveillance in HPV-associated cancers, particularl...
Circulating Cell-free Human Papillomavirus DNA as a Tumor Marker in Recurrent or Metastatic Cervical Cancer: A Pilot Study
Circulating Cell-free Human Papillomavirus DNA as a Tumor Marker in Recurrent or Metastatic Cervical Cancer: A Pilot Study
PURPOSE: Monitoring of circulating human papillomavirus (HPV) cell-free DNA (cfDNA) is a minimally invasive approach for surveillance in HPV-associated cancers, particularly cervic...
Monitoring Circulating Cell-Free HPV DNA in Metastatic and Recurrent Cervical Cancer: Clinical Importance and Implications for Treatment – A Pilot Study
Monitoring Circulating Cell-Free HPV DNA in Metastatic and Recurrent Cervical Cancer: Clinical Importance and Implications for Treatment – A Pilot Study
PURPOSE: Monitoring circulating human papillomavirus (HPV) cell-free DNA (cfDNA) is a minimally invasive approach for surveillance in HPV-associated cancers, particularly cervical ...
Monitoring Circulating Cell-free HPV DNA in Metastatic and Recurrent Cervical Cancer: Clinical Importance and Implications for Treatment - A Pilot Study
Monitoring Circulating Cell-free HPV DNA in Metastatic and Recurrent Cervical Cancer: Clinical Importance and Implications for Treatment - A Pilot Study
Abstract
Purpose
Monitoring of circulating human papillomavirus (HPV) cell-free DNA (cfDNA) is a minimally invasive approach for surveillance in HPV-associated cancers, particularl...
Cell-Free DNA Promotes Inflammation in Patients With Oral Lichen Planus via the STING Pathway
Cell-Free DNA Promotes Inflammation in Patients With Oral Lichen Planus via the STING Pathway
BackgroundDamaged and dead cells release cell-free DNA (cfDNA) that activates cyclic GMP–AMP (cGAMP) synthase (cGAS), which leads to the activation of stimulator of interferon gene...

